+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
BCMA-targeted CAR-T Cell Therapy Market by Product Type, Line Of Therapy, End User, Distribution Channel, Manufacturing Type - Global Forecast to 2030- Product Image
BCMA-targeted CAR-T Cell Therapy Market by Product Type, Line Of Therapy, End User, Distribution Channel, Manufacturing Type - Global Forecast to 2030- Product Image
Sale

BCMA-targeted CAR-T Cell Therapy Market by Product Type, Line Of Therapy, End User, Distribution Channel, Manufacturing Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078933
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

BCMA-directed CAR-T therapies are transforming the multiple myeloma treatment landscape by overcoming barriers to durable remission in relapsed and refractory cases. Market expansion is fueled by accelerated regulatory pathways and ongoing therapeutic innovation, creating opportunities for manufacturers, clinicians, and investors seeking a competitive edge in hematologic oncology.

Market Snapshot: BCMA-Directed CAR-T Landscape

The BCMA-directed CAR-T therapy market is defined by heightened demand for advanced cell-based treatment options, as standard modalities leave significant gaps for late-line multiple myeloma patients. With robust clinical trial activity, increasing regulatory approvals, and rising investments in cell therapy manufacturing infrastructure, the market demonstrates strong growth potential and accelerated adoption globally. These factors, coupled with maturing real-world evidence and broader stakeholder confidence, underscore the commercial viability of these therapies across the Americas, EMEA, and Asia-Pacific regions.

Scope & Segmentation of the BCMA-Directed CAR-T Market

  • Product Type: Allogeneic therapies and autologous constructs are the central product classes, each catering to distinct clinical and operational needs.
  • Line of Therapy: Therapeutic use spans second-line, third-line, and fourth-line or later settings, reflecting broadening clinical applications.
  • End User: Hospitals, research institutes, and specialty clinics including academic and community institutions as well as outpatient oncology centers serve as primary administration sites.
  • Distribution Channel: Hospital pharmacies and specialty pharmacies play critical roles in facilitating product handling and patient support services.
  • Manufacturing Type: Both contract manufacturing and in-house production approaches are prominent, supporting various strategies for quality control and capacity scaling.
  • Geography: The market covers the Americas (including the US, Canada, Mexico, Brazil, Argentina), EMEA (highlighting the UK, Germany, France, among others), and Asia-Pacific (notably China, India, Japan, Australia).
  • Company Coverage: Major innovators analyzed include Janssen Biotech, Bristol-Myers Squibb, Legend Biotech, and others, illustrating a blend of established and emerging players driving new solutions.

Key Takeaways for Senior Stakeholders

  • BCMA-directed CAR-T therapies are rapidly advancing from concept to commercial reality, reshaping treatment paradigms for multiple myeloma.
  • Strategic partnerships with contract manufacturers and biotechnology firms are critical for expanding production capacity and addressing supply chain complexity.
  • Clinician adoption is accelerated by maturing trial data and growing confidence in real-world outcomes, resulting in broader institutional engagement across different care settings.
  • Value-based reimbursement models and regional policy differences influence adoption rates, prompting manufacturers to adapt commercialization and pricing strategies by geography.
  • Allogeneic, off-the-shelf CAR-T products present notable potential for reducing time-to-treatment and operational costs, signaling future market shifts.
  • Technological advances in T-cell engineering and automated manufacturing platforms are poised to further reduce production timelines and enhance overall safety profiles.

Tariff Impact on the BCMA-Directed CAR-T Market

Recent US tariff measures have increased import duties on essential inputs such as viral vectors and specialized bioreactors. This elevation in input costs pressures both contract manufacturers and in-house facilities, with small and midsize firms more acutely affected. Companies are adopting vertical integration, dual sourcing, and near-shoring to cushion against margin compression and sustain supply continuity. Cross-functional collaboration, especially between procurement and technical teams, is essential for responding to these trade environment changes and optimizing total landed costs.

Methodology & Data Sources

This report utilizes a multi-tiered approach, combining interviews with industry executives, clinicians, and payers, along with data from regulatory filings, clinical trial registries, and supply chain analytics. Patent landscapes, acquisition records, and reimbursement analyses contribute to a robust, triangulated evaluation. Peer review and editorial auditing maintain data integrity throughout the process.

Why This Report Matters

  • Delivers actionable insights on emerging therapeutic and operational innovations in the BCMA-directed CAR-T market.
  • Guides strategic investment by contextualizing technology advancements, regulatory developments, and regional dynamics for key stakeholders.
  • Supports leadership teams in building resilient supply and value chains amid evolving global trade and manufacturing environments.

Conclusion

As BCMA-directed CAR-T therapies continue to define the next frontier in multiple myeloma care, stakeholders equipped with strategic insights and agile execution models are positioned to lead in clinical impact and commercial performance. Sustained innovation and cross-sector collaboration will shape the market’s evolution.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. BCMA-targeted CAR-T Cell Therapy Market, by Product Type
8.1. Introduction
8.2. Gene Constructs
8.3. Virus Vectors
9. BCMA-targeted CAR-T Cell Therapy Market, by End Users
9.1. Introduction
9.2. Cancer Research Centers
9.3. Hospitals
10. BCMA-targeted CAR-T Cell Therapy Market, by Deployment Frameworks
10.1. Introduction
10.2. Funding Sources
10.2.1. Private Sponsorships
10.2.2. Public Sources
11. Americas BCMA-targeted CAR-T Cell Therapy Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Bristol Myers Squibb
14.3.2. Janssen Biotech
14.3.3. Kite Pharma (Gilead Sciences)
14.3.4. Legend Biotech
14.3.5. Novartis AG
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. BCMA-TARGETED CAR-T CELL THERAPY MARKET MULTI-CURRENCY
FIGURE 2. BCMA-TARGETED CAR-T CELL THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. BCMA-TARGETED CAR-T CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BCMA-TARGETED CAR-T CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BCMA-TARGETED CAR-T CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BCMA-TARGETED CAR-T CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY GENE CONSTRUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY VIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRIVATE SPONSORSHIPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PUBLIC SOURCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 30. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 31. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 32. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 33. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 34. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 36. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 37. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 52. CHINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CHINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 54. CHINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 55. CHINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 56. INDIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. INDIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 58. INDIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 59. INDIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 60. INDONESIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. INDONESIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 64. JAPAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. JAPAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 66. JAPAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 67. JAPAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 68. MALAYSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MALAYSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 72. PHILIPPINES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. PHILIPPINES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 76. SINGAPORE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. SINGAPORE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 80. SOUTH KOREA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. SOUTH KOREA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 84. TAIWAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. TAIWAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 88. THAILAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. THAILAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 90. THAILAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 91. THAILAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 92. VIETNAM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. VIETNAM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 103. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 104. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 105. EGYPT BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. EGYPT BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 107. EGYPT BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 108. EGYPT BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 109. FINLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. FINLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 111. FINLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 112. FINLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 117. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ISRAEL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 125. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 127. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 128. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 129. NETHERLANDS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. NETHERLANDS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 137. NORWAY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. NORWAY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 139. NORWAY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 140. NORWAY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 141. POLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. POLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 143. POLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 144. POLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 145. QATAR BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. QATAR BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 147. QATAR BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 148. QATAR BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 161. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 163. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 164. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 165. SWEDEN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. SWEDEN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 169. SWITZERLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. SWITZERLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 173. TURKEY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. TURKEY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 175. TURKEY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 176. TURKEY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DEPLOYMENT FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FUNDING SOURCES, 2018-2030 (USD MILLION)
TABLE 185. BCMA-TARGETED CAR-T CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
TABLE 186. BCMA-TARGETED CAR-T CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this BCMA-targeted CAR-T Cell Therapy market report include:
  • Janssen Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Legend Biotech Corporation
  • bluebird bio, Inc.
  • Allogene Therapeutics, Inc.
  • Poseida Therapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Precision BioSciences, Inc.
  • Cellectis S.A.
  • Sorrento Therapeutics, Inc.

Related Topics

Related Reports

CAR T-cell Therapy - Pipeline Insight, 2025 - Product Image

CAR T-cell Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • 450 Pages
  • Global
From
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 - Product Image

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035

  • Report
  • 598 Pages
  • Global
From
CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033 - Product Image

CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033

  • Report
  • 180 Pages
  • Global
From
Autologous CAR-T Cell Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Autologous CAR-T Cell Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.